Adicet Bio Initiates First Patient Dosing in Phase 1 Study
Adicet Bio, Inc. (NASDAQ: ACET), a pioneering biotechnology company, has reached a significant milestone by dosing the first patient in its Phase 1 clinical trial. This study is aimed at evaluating ADI-270, an innovative therapy designed specifically for metastatic or advanced clear cell renal cell carcinoma (ccRCC).
Understanding the Significance of the Phase 1 Trial
Dosing the first patient marks a triumphant step forward for Adicet, as it brings their gamma delta T cell product candidate closer to addressing a critical need in oncology. As Chen Schor, the company’s President and CEO, explained, current treatments for ccRCC are often limited, creating a substantial gap in care for these patients. The pressing necessity for effective therapies calls for novel approaches like ADI-270, which has shown promising preclinical results in penetrating tumors and overcoming oppressive microenvironments.
Details of the Clinical Trial
This multicenter, open-label clinical trial targets adults diagnosed with relapsed or refractory metastatic/advanced ccRCC. Patients enrolled in the study will initially undergo lymphodepletion before receiving a single infusion of ADI-270, starting at a dose of 3E8 CAR+ cells. Depending on their responses, some patients may qualify for a second dose. The trial will comprehensively assess safety, tolerability, pharmacokinetics, and the therapy's anti-tumor activity.
About ADI-270 and Its Innovative Mechanism
ADI-270 is an allogeneic “off-the-shelf” CAR T cell therapy that specifically targets CD70, a promising biomarker commonly expressed in various malignancies, including both solid and hematological cancers. By employing a third-generation CAR structure and enhancing its efficacy with a form of the transforming growth factor-? receptor, ADI-270 aims to bypass the immunosuppressive challenges that often beset tumor treatments.
Potential Benefits for Patients
The unique design of ADI-270 is centered on enhancing exposure and retention within the body while reducing the risk of rejection. These attributes, coupled with robust tumor infiltration capabilities, position ADI-270 as a potentially game-changing option for patients afflicted with ccRCC and other CD70-positive tumors.
Exploring Renal Cell Carcinoma
Renal cell carcinoma, representing around 80% of kidney tumors, is particularly aggressive, with the clear cell variant making up the majority of cases. Unfortunately, many of those diagnosed will face advanced stages of the disease, which significantly reduces their chances of survival. While early-stage localized RCC boasts a 5-year survival rate of approximately 93%, that number drastically drops to around 15% for advanced cases.
About Adicet Bio
Adicet Bio, Inc. remains committed to revolutionizing treatment strategies for cancer and autoimmune diseases through its pioneering gamma delta T cell therapies. The company’s goal is to bring effective, durable treatments to patients who face significant challenges with existing therapies. As more data becomes available from clinical studies, Adicet aspires to offer breakthroughs in therapeutic options for individuals in dire need.
Frequently Asked Questions
What is the purpose of the Phase 1 trial for ADI-270?
The trial aims to evaluate the safety and efficacy of ADI-270 as a treatment for advanced clear cell renal cell carcinoma.
What is ADI-270?
ADI-270 is an allogeneic CAR T cell therapy designed to target CD70-positive cancers.
Who can participate in the ADI-270 trial?
Adults with relapsed or refractory metastatic/advanced clear cell renal cell carcinoma are eligible for the trial.
What are the expected outcomes of this trial?
The trial seeks to determine the safety, tolerability, and anti-tumor activity of ADI-270.
When will results from the trial be available?
Preliminary clinical data from the trial is anticipated to be reported in the first half of 2025.
